日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma

在淋巴瘤中,即使发生单抗原或双抗原丢失,接头CAR的共表达仍能保持CAR T细胞的疗效。

Riester, Zeno; Surowka, Marlena; Seifert, Nicole; Darowski, Diana; Ghosh, Arindam; Spieler, Peter; Weber, Justus; Gianotti, Reto; Freitag, Fabian; Alb, Miriam; Nerreter, Thomas; Gerhard-Hartmann, Elena; Rosenwald, Andreas; Sauer, Markus; Moessner, Ekkehard; Einsele, Hermann; Ferrara-Koller, Claudia; Klein, Christian; Hudecek, Michael; Danhof, Sophia

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy

P329G-engager:一种用于癌症免疫治疗的通用型抗体基接头平台,可进行多种组合搭配。

Marlena Surowka ,Diana Darowski ,Idil Hutter-Karakoc ,Christina Claus ,Claudia Ferrara-Koller ,Anne Freimoser-Grundschober ,Thomas Hofer ,Johannes Sam ,Reto Gianotti ,Andrzej Sobieniecki ,Denis Assisi ,John Challier ,Stephane Leclair ,Ekkehard Mössner ,Maria Amann ,Pablo Umaña ,Christian Klein

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

CEA-4-1BBL:靶向 CEACAM5 的 4-1BB 配体融合蛋白,用于与 CEA-TCB 进行顺式共刺激。

Claus Christina, Ferrara-Koller Claudia, Sam Johannes, Lang Sabine, Albrecht Rosmarie, Buser Regula B, Bommer Esther, Sala Grégory La, Nicolini Valeria G, Colombetti Sara, Bacac Marina, Umaña Pablo, Klein Christian

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy

癌症免疫治疗中新型4-1BB(CD137)激动剂药物的新兴格局

Claus, Christina; Ferrara-Koller, Claudia; Klein, Christian

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

成纤维细胞活化蛋白靶向 4-1BB 配体激动剂增强人类癌症中肿瘤内 T 细胞的效应功能

Marta Trüb, Franziska Uhlenbrock, Christina Claus, Petra Herzig, Martin Thelen, Vaios Karanikas, Marina Bacac, Maria Amann, Rosemarie Albrecht, Claudia Ferrara-Koller, Daniela Thommen, Sacha Rothschield, Spasenija Savic Prince, Kirsten D Mertz, Gieri Cathomas, Robert Rosenberg, Viola Heinzelmann-Sch

Characterization and prediction of positional 4-hydroxyproline and sulfotyrosine, two post-translational modifications that can occur at substantial levels in CHO cells-expressed biotherapeutics

4-羟脯氨酸和磺化酪氨酸位置的表征和预测,这两种翻译后修饰可在 CHO 细胞表达的生物治疗药物中大量发生

Oksana Tyshchuk, Christoph Gstöttner, Dennis Funk, Simone Nicolardi, Stefan Frost, Stefan Klostermann, Tim Becker, Elena Jolkver, Felix Schumacher, Claudia Ferrara Koller, Hans Rainer Völger, Manfred Wuhrer, Patrick Bulau, Michael Mølhøj